Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthamologists who Treat Fusarium Keratitis

Analysis of: LASIK Worries? Some May See Better with Alternatives (www.washingtonpost.com)
The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years:  Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone.  About 1 out of 4 patients that consider lasik are actually good candidates...
Analysis of: Pilot trial for toric correction with light-adjustable lens yields promising early results (ophthalmologytimes.modernmedicine.com)
The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...
Barry Schechter, MD, Director of Corneal and External Diseases
Barry Schechter, MD, Director of Corneal and External Diseases
Florida Eye Microsurgical Institute, Inc.
Analysis of: Bausch & Lomb announces acquisition of eyeonics (www.osnsupersite.com)
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% (www.medicalnewstoday.com)
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...
Analysis of: Genentech revisits plan for Avastin (www.sfgate.com)
In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is...
Analysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin (aao.org)
The American Academy of Ophthalmology said the recent decision by Genentech to limit availability of Avastin (bevacizumab) to compounding pharmacies could have a significant negative impact on the care of patients with age-related macular degeneration [AMD]. Dr. Charles Wilkinson, president of the AAO,...
Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies (www.osnsupersite.com)
Genentech, Inc.  is suspending sales of Avastin (bevacizumab) to compounding pharmacies in the United STates, in an effort to curb its non approved use for wet macular degenration. Recently, ophthalmologists have begun using the antiangiogenic cancer drug off-label to treat retinal neovascularization...
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 (www.pipelinereview.com)
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye (www.nytimes.com)
       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth (www.pnas.org)
Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...

Page : 1 2 3 4 5 6 Next1 to 10 of 59

Analytics


Generated at 2009-01-07T19:00:58.307